# Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

> **NCT03401853** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 18 (actual)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Obinutuzumab

## Key facts

- **NCT ID:** NCT03401853
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-23
- **Primary completion:** 2023-12-19
- **Final completion:** 2024-09-19
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Study terminated to end of funding.
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03401853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03401853, "Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03401853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*